Alexander Kuo1, Rachel Gomel2, Ricky Safer2, Keith D Lindor3, Gregory T Everson4, Christopher L Bowlus5. 1. Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California. 2. PSC Partners Seeking a Cure, Greenwood Village, Colorado. 3. College of Health Solutions, Arizona State University, Phoenix, AZ. 4. Division of Gastroenterology and Hepatology, University of Colorado, Denver, Colorado. 5. Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California. Electronic address: clbowlus@ucdavis.edu.
Abstract
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a fibrostenosing disease of the bile ducts associated with inflammatory bowel disease (IBD), for which the only treatment is liver transplantation. PSC progression has been defined in cohorts from referral centers or single-nation population databases. However, observations made from these cohorts have limited applicability owing to referral bias and demographic confounders. We analyzed data from the worldwide PSC Partners Patient Registry, an international online database established in 2014 to obtain information from individuals with PSC or their caretakers and compare symptoms, disease progression, and treatments of PSC in the United States and other countries. METHODS: We analyzed demographic and clinical characteristics, symptoms, and clinical outcomes of patients with PSC using the PSC Partners Patient Registry. Participants completed an online standardized questionnaire and electronic case report, providing information on age, age at symptom onset, age at PSC diagnosis, methods of diagnosis, concurrent diagnoses, family history, and medication use. RESULTS: Of 873 registrants, 811 (92.9%) had completed questionnaires and 528 (65.1%) had their PSC diagnosis confirmed; we found no significant demographic or clinical differences between patients with vs without a confirmed diagnosis. In contrast to other studies, we found a higher proportion of individuals with PSC to be female (52.5%). However, the mean age at PSC diagnosis (32.4 ± 14.7 y) and the proportion of individuals with PSC and IBD (67.1%) were similar to those from prior reports. Most cases in the database were from the United States (74.9%). More than half of the participants reported having pruritus, abdominal pain, fatigue, or sleep disturbances; rates were not significantly different among participants within vs outside the United States. There was no significant difference in treatment with ursodeoxycholic acid between participants within vs outside the United States (50.0% and 57.8%; P = .07). The median time of transplant-free survival was 21 years; transplant-free survival was associated with female sex and Crohn's disease. CONCLUSIONS: Our findings from an analysis of data from the PSC Partners Patient Registry confirm those from previous studies, although we found a higher proportion of individuals with PSC to be female. In addition to allowing efficient collection of patient-reported outcomes, the patient-driven registry allows for inclusion of previously under-represented cases of PSC.
BACKGROUND & AIMS:Primary sclerosing cholangitis (PSC) is a fibrostenosing disease of the bile ducts associated with inflammatory bowel disease (IBD), for which the only treatment is liver transplantation. PSC progression has been defined in cohorts from referral centers or single-nation population databases. However, observations made from these cohorts have limited applicability owing to referral bias and demographic confounders. We analyzed data from the worldwide PSC Partners Patient Registry, an international online database established in 2014 to obtain information from individuals with PSC or their caretakers and compare symptoms, disease progression, and treatments of PSC in the United States and other countries. METHODS: We analyzed demographic and clinical characteristics, symptoms, and clinical outcomes of patients with PSC using the PSC Partners Patient Registry. Participants completed an online standardized questionnaire and electronic case report, providing information on age, age at symptom onset, age at PSC diagnosis, methods of diagnosis, concurrent diagnoses, family history, and medication use. RESULTS: Of 873 registrants, 811 (92.9%) had completed questionnaires and 528 (65.1%) had their PSC diagnosis confirmed; we found no significant demographic or clinical differences between patients with vs without a confirmed diagnosis. In contrast to other studies, we found a higher proportion of individuals with PSC to be female (52.5%). However, the mean age at PSC diagnosis (32.4 ± 14.7 y) and the proportion of individuals with PSC and IBD (67.1%) were similar to those from prior reports. Most cases in the database were from the United States (74.9%). More than half of the participants reported having pruritus, abdominal pain, fatigue, or sleep disturbances; rates were not significantly different among participants within vs outside the United States. There was no significant difference in treatment with ursodeoxycholic acid between participants within vs outside the United States (50.0% and 57.8%; P = .07). The median time of transplant-free survival was 21 years; transplant-free survival was associated with female sex and Crohn's disease. CONCLUSIONS: Our findings from an analysis of data from the PSC Partners Patient Registry confirm those from previous studies, although we found a higher proportion of individuals with PSC to be female. In addition to allowing efficient collection of patient-reported outcomes, the patient-driven registry allows for inclusion of previously under-represented cases of PSC.
Authors: Zeinab Bakhshi; Moira B Hilscher; Gregory J Gores; William S Harmsen; Jason K Viehman; Nicholas F LaRusso; Andrea A Gossard; Konstantinos N Lazaridis; Keith D Lindor; John E Eaton Journal: J Gastroenterol Date: 2020-01-13 Impact factor: 7.527
Authors: Kate D Lynch; Roger W Chapman; Satish Keshav; Aldo J Montano-Loza; Andrew L Mason; Andreas E Kremer; Marcel Vetter; Manon de Krijger; Cyriel Y Ponsioen; Palak Trivedi; Gideon Hirschfield; Christoph Schramm; Chung Heng Liu; Christopher L Bowlus; Derek J Estes; Daniel Pratt; Charlotte Hedin; Annika Bergquist; Annemarie C de Vries; C Janneke van der Woude; Lei Yu; David N Assis; James Boyer; Henriette Ytting; Emina Hallibasic; Michael Trauner; Hanns-Ulrich Marschall; Luigi M Daretti; Marco Marzioni; Kidist K Yimam; Nicola Perin; Annarosa Floreani; Benedetta Terziroli Beretta-Piccoli; Jennifer K Rogers; Cynthia Levy Journal: Clin Gastroenterol Hepatol Date: 2019-05-14 Impact factor: 11.382
Authors: Elena Marcus; Paddy Stone; Anna-Maria Krooupa; Douglas Thorburn; Bella Vivat Journal: Health Qual Life Outcomes Date: 2021-03-20 Impact factor: 3.186
Authors: Michael D Thompson; Holly Hinrichs; Austin Faerber; Phillip I Tarr; Nicholas O Davidson Journal: J Lipid Res Date: 2022-03-25 Impact factor: 6.676